Journal
APPLIED SOFT COMPUTING
Volume 113, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.asoc.2021.107945
Keywords
COVID-19 drug repurposing; Deep learning; Convolutional neural network; XGBoost; SARS-coV-2; Antiviral drugs
Ask authors/readers for more resources
In response to the COVID-19 pandemic, this study presents a deep learning ensemble model to prioritize clinically validated antiviral drugs for potential efficacy against SARS-CoV-2. The method extracts deep features through a convolutional neural network and classifies them using an extreme gradient boosting classifier to infer potential virus-drug associations.
The alarming pandemic situation of Coronavirus infectious disease COVID-19, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a critical threat to public health. The unexpected outbreak and unrealistic progression of COVID-19 have generated an utmost need to realize promising therapeutic strategies to fight the pandemic. Drug repurposing-an efficient drug discovery technique from approved drugs is an emerging tactic to face the immediate global challenge. It offers a time-efficient and cost-effective way to find potential therapeutic agents for the disease. Artificial Intelligence-empowered deep learning models enable the rapid identification of potentially repurposable drug candidates against diseases. This study presents a deep learning ensemble model to prioritize clinically validated anti-viral drugs for their potential efficacy against SARS-CoV-2. The method integrates the similarities of drug chemical structures and virus genome sequences to generate feature vectors. The best combination of features is retrieved by the convolutional neural network in a deep learning manner. The extracted deep features are classified by the extreme gradient boosting classifier to infer potential virus-drug associations. The method could achieve an AUC of 0.8897 with 0.8571 prediction accuracy and 0.8394 sensitivity under the fivefold cross-validation. The experimental results and case studies demonstrate the suggested deep learning ensemble system yields competitive results compared with the state-of-the-art approaches. The top-ranked drugs are released for further wet-lab researches. (C) 2021 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available